Histologic findings together with the clinical and radiological context are usually sufficient to classify CGCG, but occasionally testing for TRP4, KRAS or FGFR1 mutations might be helpful in making a final diagnosis, particularly in excluding solid variants of aneurysmal bone cyst without USP6 rearrangement and “brown” tumours. The gene discussed is KRAS; the disease is neoplasm.